Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2. (November 2021)

• Record Type: Journal Article
• Authors: Deshpande, Gururaj Rao; Kaduskar, Ojas; Deshpande, Ketki; Bhatt, Vaishali; Yadav, Pragya; Gurav, Yogesh; Potdar, Varsha; Khutwad, Kirti; Vidhate, Shankar; Salunke, Asha; Patil, Chetan; Shingade, Snehal; Jarande, Kajal; Tilekar, Bipin; Salvi, Pavan; Patsuthe, Sudhir; Dange, Varsha; Kumar, Sudeep; Gurav, Shilpa; Chate, Sadhana; Abraham, Priya; Sapkal, Gajanan
• Is Part Of: International journal of infectious diseases. Volume 112(2021)
• Page Start: 103
• Page End: 110
• Publication Date: 2021-11
• Subjects: SARS-CoV-2 -- nucleocapsid -- receptor binding domain -- neutralizing antibody response -- IgG antibody response -- 240 days; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2021.09.024
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Data on perseverance of antibody responses against SARS-CoV-2 is vital and scanty 608 samples collected from 284 symptomatic/asymptomatic COVID-19 positive patients Persistence of binding antibodies observed in > 75 % cases till 240 days POD Neutralizing antibody response was seen in 80% of cases till 240 days POD Severe disease was associated with higher SRBD IgG and NAb responses Abstract: Objectives: Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein specific IgG and neutralizing antibody (NAb) responses in COVID-19 patients up to 8 months and its correlation with diverse disease spectrum. Methods: During the first wave of the SARS-CoV-2 pandemic, from 284 COVID-19 patients, 608 samples were collected up to 8 months post infection. The patients were categorized as asymptomatic, symptomatic and severe. The N and SRBD IgG and NAb titers were evaluated and correlated with clinical data. Results: A steep increase in antigen specific antibody titers was observed till 40 days post onset of the disease (POD), followed by a partial decline till 240 days. Severe disease was associated with a stronger SRBD IgG response and higher NAb titers. The persistence of antibody response was observed in 76% against N, 80% against SRBD and 80% for NAbs of cases up to 8 months POD. Conclusion: RBD and N protein specific IgG persisted till 240 days POD which correlated with NAb response, irrespective of individual`s symptomatic status indicating overall robust protection against re-infection.